One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.2337/dc08-1797. Epub 2009 Feb 5.
Michaela Diamant, Anja Cornér, Bjorn Eliasson, Jaret L Malloy, Rimma M Shaginian, Wei Deng, David M Kendall, Marja-Riitta Taskinen, Ulf Smith, Hannele Yki-Järvinen, Robert J Heine
Affiliations
- PMID: 19196887
- PMCID: PMC2671094
- DOI: 10.2337/dc08-1797
Randomized Controlled Trial
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial
Mathijs C Bunck et al. Diabetes Care. 2009 May.
Abstract
Objective: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in beta-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp-derived measures of beta-cell function, glycemic control, and body weight.
Research design and methods: Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period. Additional end points included effects on glycemic control, body weight, and safety.
Results: Treatment-induced change in combined glucose- and arginine-stimulated C-peptide secretion was 2.46-fold (95% CI 2.09-2.90, P < 0.0001) greater after a 52-week exenatide treatment compared with insulin glargine treatment. Both exenatide and insulin glargine reduced A1C similarly: -0.8 +/- 0.1 and -0.7 +/- 0.2%, respectively (P = 0.55). Exenatide reduced body weight compared with insulin glargine (difference -4.6 kg, P < 0.0001). beta-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy.
Conclusions: Exenatide significantly improves beta-cell function during 1 year of treatment compared with titrated insulin glargine. After cessation of both exenatide and insulin glargine therapy, beta-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy.
Figures
Figure 1
Protocol flow chart and baseline characteristics of the study population. Data represent means ± SEM.
Figure 2
Time course for A1C (A) and fasting plasma glucose (B). SMBG concentrations before (C) and after (D) 52 weeks of treatment. Changes in body weight (E) and insulin sensitivity were measured as the M value (F). Data are means ± SEM. ●, exenatide; ○, insulin glargine; ■, pretreatment; □, 52 weeks on-drug; ▨, 4 weeks off-drug. Vertical black line at 52 weeks represents cessation of study medication. BB, before breakfast; AB, after breakfast; BL, before lunch; AL, after lunch; BD, before dinner; AD, after dinner; BT, bedtime.
Figure 3
C-peptide concentrations during hyperglycemic clamp and ratio to pretreatment in the exenatide (A and C)- and insulin glargine (B and D)-treated group. Data represent mean ± SEM in A and B and geometric mean ± SEM in C and D. AIRarg, C-peptide response to arginine at 15 mmol/l glucose concentration; 1st phase, first-phase C-peptide response to glucose; 2nd phase, second-phase C-peptide response to glucose. See
research design and methods
for calculations of β-cell function measures. ●, ■, pretreatment; ○, □, 52-weeks on-drug; ■, ▨, 4 weeks off-drug.
Similar articles
- Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.
Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Järvinen H, Diamant M. Bunck MC, et al. Diabetes Care. 2011 Sep;34(9):2041-7. doi: 10.2337/dc11-0291. Diabetes Care. 2011. PMID: 21868779 Free PMC article. Clinical Trial. - Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Barnett AH, et al. Clin Ther. 2007 Nov;29(11):2333-48. doi: 10.1016/j.clinthera.2007.11.006. Clin Ther. 2007. PMID: 18158075 Clinical Trial. - Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Heine RJ, et al. Ann Intern Med. 2005 Oct 18;143(8):559-69. doi: 10.7326/0003-4819-143-8-200510180-00006. Ann Intern Med. 2005. PMID: 16230722 Clinical Trial. - Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review. - Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Ryan GJ, Moniri NH, Smiley DD. Ryan GJ, et al. Am J Health Syst Pharm. 2013 Jul 1;70(13):1123-31. doi: 10.2146/ajhp120168. Am J Health Syst Pharm. 2013. PMID: 23784159 Review.
Cited by
- Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study.
Kondo Y, Satoh S, Terauchi Y. Kondo Y, et al. Diabetol Int. 2024 Apr 3;15(3):474-482. doi: 10.1007/s13340-024-00717-6. eCollection 2024 Jul. Diabetol Int. 2024. PMID: 39101164 - Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes.
Moon JH, Choe HJ, Lim S. Moon JH, et al. J Diabetes Investig. 2024 Jun;15(6):669-683. doi: 10.1111/jdi.14221. Epub 2024 Apr 27. J Diabetes Investig. 2024. PMID: 38676410 Free PMC article. Review. - Metabolic-Bariatric Surgery for Type 2 Diabetes: Time(ing) for a Change.
Purnell JQ. Purnell JQ. Diabetes. 2024 Apr 1;73(4):542-544. doi: 10.2337/dbi23-0022. Diabetes. 2024. PMID: 38507589 No abstract available. - Beta-cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?
Sayyed Kassem L, Rajpal A, Barreiro MV, Ismail-Beigi F. Sayyed Kassem L, et al. J Diabetes. 2023 Oct;15(10):817-837. doi: 10.1111/1753-0407.13446. Epub 2023 Jul 31. J Diabetes. 2023. PMID: 37522521 Free PMC article. Review. - Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes: Part 2.
Hao S, Umpierrez GE, Vellanki P. Hao S, et al. Endocrinol Metab Clin North Am. 2023 Mar;52(1):39-47. doi: 10.1016/j.ecl.2022.07.004. Epub 2022 Nov 18. Endocrinol Metab Clin North Am. 2023. PMID: 36754496 Free PMC article. Review.
References
- Kahn SE: The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3– 19 - PubMed
- Riddle MC: Timely initiation of basal insulin. Am J Med 2004; 116: 3S– 9S - PubMed
- Turner RC, Cull CA, Frighi V, Holman RR: the UKPDSG. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005– 2012 - PubMed
- Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628– 2635 - PubMed
- DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092– 1100 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical